Transforming growth factor (type beta) promotes the addition of chondroitin sulfate chains to the cell surface proteoglycan (syndecan) of mouse mammary epithelia by unknown
Transforming Growth Factor (Type/3) Promotes 
the Addition of Chondroitin Sulfate Chains to 
The Cell Surface Proteoglycan (Syndecan) of 
Mouse Mammary Epithelia 
Alan Rapraeger 
Department of Pathology, University of Wisconsin, Madison, Wisconsin 53706 
Abstract.  Cultured monolayers of NMuMG mouse 
mammary epithelial cells have augmented amounts of 
cell surface chondroitin  sulfate glycosaminoglycan 
(GAG) when cultured in transforming growth factor-/3 
(TGF-/3),  presumably because of increased synthesis 
on their cell surface proteoglycan (named syndecan), 
previously shown to contain chondroitin  sulfate and 
heparan  sulfate GAG. This increase occurs throughout 
the monolayer as shown using soluble thrombospondin 
as a binding probe.  However, comparison of staining 
intensity of the GAG chains and syndecan core protein 
suggests variability among cells in the attachment of 
GAG chains to the core protein.  Characterization  of 
purified syndecan confirms the enhanced addition of 
chondroitin sulfate in TGF-/3:  (a) radiosulfate incorpo- 
ration  into chondroitin  sulfate is increased 6.2-fold in 
this proteoglycan fraction and heparan  sulfate is in- 
creased  1.8-fold,  despite no apparent increase in 
amount of core protein per cell, and (b) the size and 
density of the proteoglycan are increased,  but reduced 
by removal of chondroitin  sulfate.  This is shown in 
part by treatment of the cells with 0.5 mM xyloside 
that blocks the chondroitin  sulfate addition without 
affecting heparan  sulfate.  Higher xyloside concentra- 
tions block heparan  sulfate as well and syndecan ap- 
pears at the cell surface as core protein without GAG 
chains.  The enhanced amount of GAG on syndecan is 
partly attributed to an increase in chain length. 
Whereas this accounts for the additional heparan  sul- 
fate synthesis, it is insufficient to explain the total in- 
crease in chondroitin  sulfate; an approximately three- 
fold increase in chondroitin  sulfate chain addition 
occurs as well, confirmed by assessing chondroitin 
sulfate ABC lyase (ABCase)-generated chondroitin 
sulfate linkage stubs on the core protein.  One of the 
effects of TGF-~ during embryonic tissue interactions 
is likely to be the enhanced synthesis of chondroitin 
sulfate chains on this cell surface proteoglycan. 
T 
RANSFORMING growth factor-B (TGF-/3)' is a 25-kD 
polypeptide dimer that elicits  various cellular behav- 
iors,  including  reduced  proliferation  and  enhanced 
differentiation  of epithelial cells (for reviews, see references 
16 and 33). Platelets  are a rich source of the growth factor 
(1, 37), and porcine platelets  contain  two types, termed/3, 
and ~, which occur primarily as homodimers.  These fac- 
tors are  equivalent  to the cartilage-inducing  factors  (32). 
More recently, the potential biological effects of these factors 
have been extended to amphibian  development where a pro- 
tein  similar  to TGF-B2 is  reported to induce mesodermal 
structures at the time of gastrulation  (25). 
The mechanisms whereby TGF-/3 affects cells are not com- 
pletely understood. The factor binds to at least three proteins 
at the surfaces of most cells (3, 31), and the cellular response 
1.  Abbreviations  used in  this paper:  ABCase,  chondroitin  sulfate ABC 
lyase; CM-PBS, calcium- and magnesium-containing  PBS; FN, fibronec- 
tin;  GAG, glycosaminoglycan;  PG,  proteoglycan;  TGF-/3, transforming 
growth factor (type 8); TSP, thrombospondin. 
to the growth factor is reported to vary with the identity  of 
the occupied receptor.  A  cellular  response that  has  been 
studied in increasing detail is the enhanced deposition of ma- 
trix components and the augmented expression of their re- 
ceptors.  For example,  the expression of collagen and fibro- 
nectin (FN) is increased in a variety of cell types, the latter 
via regulation  of mRNA levels (11, 13). 
Synthesis of chondroitin  sulfate proteoglycan (PG) is also 
augmented (2, 5), due in part if not entirely, to enhanced ex- 
pression of their core proteins (2). In addition,  preadipocytes 
and human fibroblasts treated with TGF-/3 show an enhanced 
expression  of integrin,  an FN receptor,  via regulation  at the 
pre- and posttranslational  processing steps (12, 24). Thus, 
the ability of  cells to deposit and recognize their extracellular 
matrix is dramatically  altered, often correlated with a change 
in their shape. 
Previous work (22) identified  an integral  membrane PG 
polarized to the basolateral  cell surface of mouse mammary 
epithelia.  Subsequent examination  of its tissue distribution 
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but is detected in abundance on most epithelia (9). Recently, 
the PG has been further identified by deduction of its pri- 
mary amino acid sequence from DNA cloning data and has 
been named syndecan (29). On NMuMG mammary epithe- 
lial cells, syndecan has been shown to bear primarily bepa- 
ran sulfate GAG chains, in addition to a minor proportion of 
chondroitin sulfate (18). The heparan sulfate chains mediate 
binding to components of the extracellular matrix, including 
FN  (28),  interstitial collagens (15),  and thrombospondin 
(TSP) (34). The PG is thus proposed to be a matrix receptor 
with a role in cell adhesion to the extraceUular matrix, simi- 
lar to roles suggested for cell surface heparan sulfate PGs of 
other cells (for review, see reference 26). However,  the po- 
tential regulation and role ofchondroitin sulfate on syndecan 
remains unknown. In an attempt to determine if the expres- 
sion of syndecan is affected by TGF-B, we recently examined 
the amount of  cell surface GAG on these calls in the presence 
of the growth factor and reported that cell surface GAG in- 
creased "~2.5-fold  due in part to an increased synthesis of 
chondroitin sulfate, but that the amount of PG core protein 
remained relatively unchanged. This suggested that the struc- 
ture of syndecan was altered by an increase in its proportion 
of chondroitin sulfate. This report specifically examines the 
possibility that additional chondroitin sulfate chains are initi- 
ated on this PG core protein when the cells are treated with 
TGF-a. 
Materials and Methods 
Cell Culture and Radiolabeling 
NMuMG  mouse mammary epithelial cells (passages  13-25) were main- 
tained in bicarbonate-buffered DME (Gibco Laboratories,  Grand Island, 
NY) containing 10% FBS (Tissue Culture Biologicals,.Tulare, CA) and la- 
beled with [35S]sulfuric  acid in a low sulfate formulation as described pre- 
viously (7, 23).  Human TGF-Bj was obtained from R  &  D  Systems Inc. 
(Minneapolis, MN), suspended in 4 mM HCI in 1 mg/ml BSA and flash- 
frozen in liquid nitrogen and stored at -70°C until use. Cells were treated 
for 24 h with 3-5 ng/ml TGF-/~ at subeonfluant densities in tissue culture 
dishes or on glass coverslips (23). For treatment with xyloside, methylum- 
belliferyI-B-o-xylopyranoside (Sigma Chemical Co.,  St.  Louis,  MO) was 
dissolved at 500 mM in Me2SO and diluted directly into the culture medi- 
um with vigorous mixing. Control cultures were in Me2SO alone. 
Specific Localization of Cell Surface GAG 
via TSP Binding 
Cells on coverslips were fixed for 24 h  in calcium- and magnesium-con- 
taining PBS (CM-PBS) containing 4% formaldehyde, washed and blocked 
in 50 mM glycine. Selected coverslips were then treated with 200/zl of CM- 
PBS containing 2 mg/ml BSA and either (a) no enzyme; (b) 1 mIU/ml of 
heparitinase (ICN Radiochemicals, Irvin¢, CA) in the presence of 50/zg/ml 
chondroitin sulfate carrier (types A and C; Sigma Chemical Co.);  (c) 50 
mU/ml ABCase (ICN Radiocbemicals); or (d) a combination of both en- 
zymes. After a 60-min incubation at room temperature, the coverslips were 
washed and incubated for 60 min with 200/~l of TSP (25/~g/ml), provided 
by Dr.  Deane Mosher,  University of Wisconsin-Madison.  After washing, 
the coverslips were incubated in serum antibodies specific for TSP (1"100 
dilution, supplied by Dr. Mosher) and a monoclonal antibody (mAb 281.2; 
50/~g/ml; reference 14) to the PG core protein and immunostained as de- 
scribed previously (23). 
Isolation and Purification of Syndecan 
After a 24-h incubation in radiosulfate with or without TGF-~, the cells were 
recovered by scraping into calcium- and magnesium-ftve-PBS containing 
0.5 mM EDTA on ice and centrifuging (200 g). The cells were initially ex- 
tracted with isotonic, 1% Triton X-100 at pH 5.0 to release soluble contents, 
then syndecan was released by a subsequent treatment in an identical solu- 
tion containing 0.5 M KCI (21). DNA in the remaining cell pellet was mea- 
sured as described previously (23). Syndecan was purified on an antibody 
(mAb 281.2) affinity column specific for its core protein (14) followed by 
binding to an HPLC AX-300 anion exchange column (Isco Inc., Lincoln, 
NE) in 8 M urea and elution at 1.0 M NaC! in a salt gradient. Trypsin treat- 
ment of cell surfaces to remove syndecan core protein was performed as de- 
scribed previously (18). 
Structural Analysis 
Quantification of  Radiolabel in Chondroitin Sulfate and Heparan Sulfate 
GAG. Purified PG or GAG chains were dialyzed into ABCase digestion 
buffer containing 0.1%  Triton X-100 (21),  incubated with or without 50 
mU/ml ABCase for 60 rain and spotted via a dot-blot apparatus (V &  P 
Scientific Inc., San Diego, CA) onto cationic nylon (Zeta-Probe; Bio-Rad 
Laboratories, Cambridge,  MA) which retains PG and intact GAG chains 
(19). Dots were dried and assessed by scintillation counting (LS-5800 detec- 
tor; Beckman Instruments, Paio Alto, CA) in BioSafe (Research Products 
International Corp., Prospect, IL) cocktail to determine 35SO4 incorporation. 
Alternatively, the dot blots were subjected to autoradiography (X-OMAT 
film; Eastman Kodak Co.,  Rochester, NY).  The difference between non- 
digested and enzyme-treated samples reflected incorporation into chondroi- 
tin sulfate. To assess beparan sulfate, selected samples on Zeta-Probe dots 
were subjected to nitrous acid digestion in 3.6 M  acetic acid containing 
0.24 M sodium nitrite for 90 rain, repeated for an additional 90 rain, then 
washed in 0.7 M NaCI buffered at pH 8.0 with 10 mM Tris to remove bepa- 
ran sulfate fragments (19). ABCase digestion followed by the nitrous acid 
treatment removes >95% of the radiolabel from syndecan. 
Size of Syndecan and Its GAG Chains.  Chromatographic procedures 
and size estimates of syndecan from nontreated NMuMG cells have been 
published previously (15, 20). Briefly, cells were extracted directly in sam- 
ple buffer, electropboresed on 3-15% polyacrylamide gels as described by 
Koda et al. (15). The PG was electropboretically transferred to Zeta-Probe 
by the method of Towbin et al.  (36)  using one-quarter strength transfer 
buffer at 100 mA for 3 h. Core protein was detected by mAb 281.2 immuno- 
staining as described previously (23) and below. To assess GAG chain size, 
purified PG was treated overnight with 0.1 N NaOH in 1 M sodium boroby- 
dride to release the chains, which were then chromatographed on Sepbarose 
CL-6B (Pharmacia Fine Chemicals,  Piscataway,  NI) in 10 mM Tris (pH 
8.0), 8 M urea and 1% Triton X-100. Incorporation into chondroitin sulfate 
or heparan sulfate was determined for each column fraction spored on cat- 
ionic nylon as described above. Size estimates of the GAG chains were de- 
rived from published data using chondroitin sulfate standards (20). 
Core Protein and Chondroitin Sulfate Linkage Sites. Purified syndecan 
was incubated with or without ABCase and spotted in twofold serial dilu- 
tions on cationic nylon. To quantify relative amounts of core protein, the 
blots were incubated with monoclonal antibody (mAb 281.2, 50/~g/ml) as 
described previously (23). Alternatively, identical blots were incubated with 
a  1:3,000 dilution of a rabbit serum antibody (R44, kindly supplied by Dr. 
John Couchman, University of Alabama) directed against the unsaturated 
uronic acid products of ABCase digestion (6). Unlike certain monocional 
antibodies that show specificity for chondroitin sulfate type, this antibody 
recognizes equally  the unsaturated  uronic acid  remaining after ABCase 
digestion of chondroitin 4-sulfate, -6-snifate, and nonsulfated chondroitin 
(J.  Couchman,  personal communication).  The blots were then incubated 
with secondary horseradish peroxidase-conjngated anti-rat or anti-rabbit 
antibodies (Jackson Immuno Research Laboratories Inc., Avondale, PAL 
respectively, and detected by incubation in 30 mM sodium acetate, 0.2 mM 
thimerosal,  4  mM  succinic acid,  1 mM  3-amino-9-ethylcarbazole,  and 
0.01% hydrogen peroxide. Blots were photographed (P/N 55 film; Polaroid 
Corp., Cambridge,  MA). 
Density Analysis. 35SO4-1abeled and purified PG (0.5 ml) was treated 
with or without 50 mU/ml ABCase or 0.01 mIU/ml heparitinase containing 
2/~g/ml chondroitin sulfate A and chondroitin sulfate C for 120 min at 20°C. 
Samples were then loaded onto step gradients of cesium trifluoroacetate 
consisting of 1.5-ml steps at 1.35, 1.5, and 1.75 g/ml in l0 mM Tris (pH 7.5) 
containing 0.2%  Triton X-100.  The gradients were centrifuged in polyal- 
Iomer tubes in (SW 50.1; Beckman Instruments, Inc., Palo Alto, CA) rotor 
at 44,000 g, 72 h, 4°C. Gradients were collected from the top into 0.3-ml 
fractions using a gradient collector (Haake Buchler Instruments, Inc., Sad- 
dle Brook, NJ), fractions weighed for density determinations, then diluted 
to 6 ml and spotted onto Zeta-Probe, and immunostained with mAb 281 for 
core protein localization. The blot was then dried and the bound radioactiv- 
ity from individual fractions assessed by scintillation counting. 
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and Heparan Sulfate on the Cell Surface PG  from 
TGF-/~-  Treated Cells 
No TGF-/~  +TGF-/~ 
[3s]SO4 DPM/~g DNA*  1  2.70 (0.49) 
Percent degraded by ABCase  20.2  (2.9)t  46.3  (1.6) 
Percent degraded by HNO2  78.2 (6.0)  51.9 (1.3) 
* Expressed as a proportion of the incorporation in no TGF-~. 
Number in parentheses is SEM, n  =  6 different experiments. 
Results 
Incorporation of  Radiosulfate into Cell Surface 
Chondroitin Sulfate and Heparan Sulfate GAG in 
the Presence of TGF-~ 
Previous work suggested that NMuMG cells show increased 
GAG at their surfaces when cultured in TGF-flt or TGF-/~e 
and that the majority of the increase was in chondroitin sul- 
fate. To quantify this increase more specifically, the cell sur- 
face PG (syndecan) that has been characterized on these cells 
(22) was isolated after a 24-h radiosulfate label in the pres- 
ence or absence of the growth factor, purified on an antibody 
affinity column specific for its core protein,  and degraded 
with ABCase and/or nitrous acid to quantify "SO+ incorpo- 
ration  into  chondroitin  sulfate and/or  heparan  sulfate,  re- 
spectively (Table I). In the nontreated cells, the bulk of the 
incorporation (78. 2 %) is into heparan sulfate, whereas chon- 
droitin sulfate accounts for a minor proportion (20. 2 %). This 
confirms earlier work that demonstrated syndecan to be a 
heparan sulfate-rich hybrid PG (8,  20). 
In the presence of TGF-13, combined radiosulfate incorpo- 
ration into these two GAGs increases an average of 2.7-fold/ 
cell compared to nontreated cells (Table I). This incorpora- 
tion occurs nearly equally into the two GAG types; heparan 
sulfate accounts  for 51.9%  of the  incorporation,  whereas 
46.3%  is in chondroitin  sulfate.  The chondroitin  sulfate is 
also susceptible to chondroitin AC lyase, indicating that the 
increase  is  in  chondroitin-4-sulfate  and  chondroitin-6-sul- 
Figure l.  Localization  of cell  surface  heparan  sulfate or chondroitin  sulfate GAG chains  by TSP binding.  Newly confluent NMuMG 
monolayers were cultured for 24 h in the absence (A-D) or presence (E-H) of 3 ng/ml TGF-~. The monolayers were treated with ABC- 
ase (B and F), heparitinase (Cand G) or both enzymes (D and H), fixed, and then incubated with TSP (10 gg/ml). The washed monolayers 
were stained with mAb 281.2 specific for the PG core protein (A and E) or anti-TSP IgG (B-D, F-H) and localized with TRITC-conjugated 
anti-rat IgG and FITC-conjugated anti-rabbit IgG, respectively. A, B, E, and F are double staining of the same field. Note that these cells 
form lateral junctions  that impair the penetration  of macromolecules  such as antibodies and TSP (21, 22) and that the nontreated cells 
show a high degree of polarization;  e.g., PG is sequestered to the basolateral cell surface and is unavailable for staining. Control staining 
with nonspecific antibodies  is negative. 
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augmented incorporation per microgram DNA in the pres- 
ence of TGF-/~, these proportions indicate that heparan sul- 
fate is increased ,,ol.8-fold and chondroitin sulfate 6.2-fold. 
Specific Localization of Core Protein, Heparan 
Sulfate, and Chondroitin Sulfate on the Cell Surface 
To determine if the augmented chondroitin sulfate synthesis 
is a response of all the cells in the monolayer, or limited to 
a subset of the cells, a procedure was used that visualized the 
distribution of the GAG chains at the cell surface. This was 
based on the observation that TSP binds to heparan sulfate 
and chondroitin sulfate (17). The binding to heparan sulfate 
has been confirmed using the NMuMG cell surface PG (34). 
In addition, chondroitin-rich syndecan from TGF-~-treated 
cells binds to TSP affinity columns via either GAG chain 
(Rapraeger, A.,  unpublished observations). Thus,  incuba- 
tion  of fixed  NMuMG  cell  monolayers with  either  mAb 
281.2,  specific for the PG core protein, or with exogenous 
TSP, which binds GAG chains, allows the colocalization of 
these structural components. In untreated NMuMG mono- 
layers, the antibodies and TSP are restricted to the apical cell 
surface due to impassable lateral cell junctions (21). At this 
surface, the PG is seen on those cells which have yet to com- 
pletely polarize their basolateral antigens (Fig.  1 A). These 
same cells bind exogenous TSP and the binding is abolished 
if cell surface GAG is removed with a combined treatment 
Figure 2. Comparison of  chondroitin sulfate and core protein distri- 
bution. Monolayers in 3 ng/ml of TGF-fl were treated with hepari- 
tinase and stained with mAb 281.2 and TSP binding, as in Fig. 1, 
E and G, to localize core protein (A) and chondroitin sulfate (B), 
respectively. Note the dissimilarities in core protein and GAG dis- 
tribution.  Bar, 10 #m. 
with ABCase and heparitinase (reference 34; Fig.  1 D). In 
addition, specific enzyme digestion of one GAG type, leav- 
ing the other, can be used to demonstrate the binding at- 
tributable to each type; binding  is  primarily  via heparan 
sulfate (Fig. 1 B), whereas only rare cells bind TSP via chon- 
droitin sulfate (Fig.  1 C). 
In contrast to untreated cells, almost all of the cells fail to 
polarize the PG to the basolateral cell surface when cultured 
in TGF-fl (23).  This widespread apical distribution of the 
cell surface PG is confirmed by localization of its core pro- 
tein (Fig. 1 E). It is also demonstrated by the binding of TSP 
to the apical surface of all cells in monolayers cultured in 
TGF-/3. TSP binding to the cells is via cell surface GAG as 
treatment with ABCase and heparitinase abolishes the TSP 
staining  (Fig.  1 H).  In addition, these cells bind TSP via 
chondroitin sulfate (Fig.  1 G) as wetl as  heparan  sulfate 
chains (Fig. 1 F) that allows visualization of  both GAG types 
throughout the  monolayer,  and  demonstrates  that  the  in- 
creased synthesis of chondroitin sulfate occurs on most,  if 
not all, of the cells. 
However, staining for core protein and TSP binding at the 
apical cell surface is not uniform. Cells that fail to stain in- 
tensely for core protein are nonetheless often seen to bind 
TSP (Fig. 2). In contrast, some ceils stain intensely for core 
protein but bind very little TSP. This lack of uniformity may 
indicate variability among cells in the numbers and/or types 
of chains decorating the cell surface core protein. In addi- 
tion, the possibility exists that a cell surface PG(s) in addi- 
tion to syndecan is being regulated by TGF-~. 
TGF-{3 Promotes Synthesis of  More GAG on Syndecan 
An increase in the density and size of syndecan supports the 
conclusion that the enhanced cell surface chondroitin sulfate 
is on this PG. 
Cell Surface PG Has an Increased Density. Purified syn- 
decan from cells treated with or without TGF-/3 was cen- 
trifuged to  equilibrium  in  cesium  trifluoroacetate density 
gradients. The PG distribution on the gradients was deter- 
mined by quantification of 3sSO4 label and detection of mAh 
281-recognized core protein on immunoblots. The PG from 
nontreated cells distributes in a  single peak with a  modal 
density of 1.55  g/ml  (Fig.  3 A).  Staining for core protein 
shows a similar distribution, although PG at the higher den- 
sities shows less core protein staining per dpm than at lower 
densities, suggesting that more GAG is attached per core pro- 
tein at higher densities. This confirms the heterogeneity de- 
scribed previously for this molecule (20) and may explain the 
variable core protein versus TSP staining described above. 
PG from cells treated with TGF-3 also distributes as a sin- 
gle peak in the density gradient, although at a greater modal 
density than the control. In addition, the shift in density of 
the PG is duplicated by a shift of the core protein recognized 
by mAb 281. The amount of core protein on the gradient is 
approximately the same, as PG from equal numbers of cells 
was loaded, but the total radiosulfate in the PG sample from 
TGF-/%treated cells is  approximately twofold greater and 
this accounts for the shift of the core protein to a  greater 
density. 
Removal of chondroitin sulfate via ABCase digestion re- 
moves 24 % of the label from the control PG preparation and 
49 % from the PG of treated cells. This has a slight, if any, 
effect on the density of the control PG, whereas the density 
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Figure 4.  Blockage of chon- 
droitin  sulfate  and  heparan 
sulfate attachment  to  synde- 
can  by  xyloside.  [3~S]GAG 
was quantified  on purified syn- 
decan  from cells cultured in 
TGF-/L  Chondroitin  sulfate 
(CS) and heparan sulfate (HS) 
are identified by susceptibility 
to ABCase and nitrous acid, 
respectively. 
Figure 3.  Comparison  of the density of syndecan from TGF-/~- 
treated and nontreated cells. Purified syndecan from cells cultured 
in the absence (o) or presence (o) of TGF-/~ was centrifuged on 
cesium trifluoroacetate gradients either intact (A), or after treat- 
ment with ABCase (B) or heparitinase (C). Aliquots of gradient 
fractions were spotted on cationic  nylon and  stained with mAb 
281.2 to localize core protein (dot blot insets) and then assessed for 
[3sS]GAG radioactivity  (c,  control;  t,  +  TGF-/3). Free heparan 
sulfate chains sediment at the same density (,'ol.6  g/ml) as the shoul- 
der in 6". Material from equal numbers of cells was loaded on each 
gradient. 
of the PG from TGF-~-treated cells is reduced to that of the 
control (Fig.  3 B). 
Digestion with heparitinase generates two peaks in the gra- 
dient (Fig. 3 C). A peak at "01.6 g/ml is seen as a shoulder 
on peaks containing PG from both control and TGF-/3-treat- 
ed cells and corresponds to the density of heparan sulfate 
fragments that are generated by the digestion and that are re- 
tained on the cationic nylon blot. In control samples, the core 
protein retaining chondroitin sulfate is found at "01.47 g/ml 
and contains ,030% of the initial radioactivity. This propor- 
tion is slightly higher than expected (20%) and may reflect 
some beparan sulfate remnants attached to the core protein. 
In  contrast  to  controls,  the  chondroitin  sulfate-decorated 
core protein from TGF-/$-treated cells retains ,',,60% of the 
radiolabel and is at a density of 1.52  g/ml.  Thus, the core 
protein bears more radiolabeled GAG than the control PG 
preparation shown in Fig.  3 A and more than either prep- 
aration shown in Fig. 3 B, yet bands at a lower density, again 
suggesting that this chondroitin sulfate-rich configuration is 
less dense than the core protein bearing heparan sulfate. 
PG Has an Increased Size That Is Prevented by Treat- 
ment with Xyloside.  The synthesis of heparan sulfate and 
chondroitin sulfate on the core protein is affected by culture 
of NMuMG cells in methylumbelliferyl-B-D-xylopyranoside 
(xyloside), which competes with xylose attached to the core 
protein for initiation and synthesis of GAG linkage regions. 
The xyloside differentially affects chondroitin sulfate com- 
pared to heparan sulfate synthesis, as shown by analysis of 
PG derived from cells cultured in TGF-B in the presence of 
various concentrations of the inhibitor (Fig. 4).  In the ab- 
sence of xyloside, 44% of the radiolabel in the PG is chon- 
droitin sulfate and 56%  is  in heparan sulfate.  In xyloside 
concentrations up to 0.5  raM,  however, the incorporation 
into chondroitin sulfate is reduced by up to 80% with only 
a slight reduction in heparan sulfate. In contrast, an increase 
in xyloside concentration to 5 mM also affects heparan sul- 
fate, which is reduced by 77% compared to a 90% reduction 
in chondroitin sulfate. 
Examination of the size of the PG derived from cells cul- 
tured in the presence of xyloside shows a differential reduc- 
tion in its size as the attachment of  chondroitin sulfate or both 
GAG types is prevented. In cells cultured in the absence of 
TGF-/3, the PG size distribution is broad with a median size 
of 190 kD (Fig. 5). Culture in the presence of up to 0.5 mM 
xyloside reduces the size distribution only slightly, consis- 
tent with chondroitin sulfate having only a minor contribu- 
tion to its overall size, and fails to reduce the heterogeneity 
in its distribution.  However, 5 mM xyloside, which affects 
heparan sulfate addition as well, reduces the size of the PG 
essentially to a  single protein band of 69 kD (Fig.  5). 
PG derived from cells cultured in TGF-/3 is increased in 
size (Fig. 5). It migrates with a median size of 280 kD on 
gradient PAGE.  This  is  confirmed by chromatography on 
Sepharose CL-4B where it elutes at a Kay of 0.25 compared 
to the control at a K,v of 0.33.  This size increase is largely 
because of additional chondroitin sulfate synthesis, as it is 
abolished if the cells are cultured in 0.5 mM xyloside (Fig. 
5). At this concentration, the PG bearing primarily heparan 
sulfate chains is nearly of the same size and modal distri- 
bution as nontreated cells. In 5 mM xyloside, the TGF-B- 
treated cells express syndecan as a single protein band of 69 
kD, similar to cells in the absence of the growth factor. De- 
spite the failure to acquire its GAG chains, this protein still 
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5 mM xyloside: susceptibility of synde- 
can core protein. Cells cultured in TGF- 
fl and 5 mM xyloside were scraped and 
treated with or without trypsin. Cell ex- 
tracts were then assessed for syndecan 
core protein as in Fig. 5. Arrow shows 
position of core protein. 
Figure 5. PAGE  analysis of the size of syndecan from ceils treated 
with various concentrations of xyloside. Monolayers were cultured 
in xyloside (either 0, 0.5, or 5 mM) in the absence or presence of 
TGF-B, and then were scraped and extracted directly in PAGE  sam- 
ple buffer. After PAGE chromatography and transfer to cationic 
nylon, the distribution of syndecan core protein was assessed by 
staining with mAb 281.2. Molecular sizes were determined by com- 
parison with known molecular mass standards. 
appears at the cell surface. The denuded core protein is pres- 
ent in extracts of cells cultured in 5 mM xyloside, but is ab- 
sent if the cell surfaces are treated with mild trypsin before 
extraction (Fig. 6). 
Increased Size of the PG Is because of 
Increased GAG Chain Length and Numbers 
of Chondroitin Sulfate Chains 
Examination of the size of the heparan sulfate and chondroi- 
tin sulfate GAG chains released from the cell surface PG by 
alkaline borohydride treatment shows that they are both in- 
creased in length in cells cultured in TGF-/~. The heparan 
sulfate chains elute from Sepharose CL-6B with  a  modal 
K,v of 0.28 compared to the control at 0.37 (Fig. 7 A). Esti- 
mates of the chain sizes of 61 and 37 kD, respectively, indi- 
cate an overall increase in size of 1.7-fold. This increase in 
size closely parallels the 1.8-fold increase in synthesis of this 
GAG type (cf., Table I). 
The chondroitin sulfate chains are also increased in size, 
although they remain shorter than the heparan sulfate chains. 
Chains  from cells cultured in the presence or absence of 
TGF-/3 elute from Sepharose CL-6B with Kav~ of 0.41  and 
0.54 (Fig. 7 B), respectively, and are estimated to be 31 and 
17 kD. However, this 1.8-fold increase in length cannot ac- 
count for the entire 6.2-fold increase in this GAG type. 
To achieve the total increase in chondroitin sulfate synthe- 
sis on syndecan, an additional threefold increase must be ac- 
counted for. One possible explanation is that more chains are 
initiated on the core protein. However, it is also possible that 
the  number of chains  initiated on the core protein is  not 
changed, and, rather, that syndecan from untreated cells has 
some very short chondroitin sulfate chains which escape de- 
tection and these chains become much longer in TGF-/~. To 
rule out the latter possibility, we examined the number of 
linkage stubs remaining on the core protein after ABCase 
digestion. This procedure trims the chondroitin sulfate chain 
into unsaturated disaccharides and generates an unsaturated 
uronic acid capping the linkage region that remains attached 
to the core protein. The remaining stub would be irrelevant 
to original chain length and is recognized by a specific anti- 
body (R44, courtesy of  J. Couchman; reference  6) that equally 
recognizes chondroitin-4-sulfate or 6-sulfate or nonsulfated 
chondroitin. 
To test the efficacy of the procedure, PG with or without 
ABCase-generated linkage stubs  was  immobilized on cat- 
ionic nylon and  stained with antibody R44.  This demon- 
strates that PG containing intact chondroitin sulfate and hep- 
aran sulfate chains is not stained by the antibody (Fig. 8 A). 
Scintillation counting of  the dots verified that the PG is quan- 
titatively retained on the blot. In addition, the antibody fails 
to stain after ABCase treatment if the linkage region is re- 
leased from the core protein by alkali (Fig. 8 B). The unsatu- 
rated disaccharides generated by ABCase are not retained on 
the blot (19),  and the released linkage region presumably 
fails to bind as well. However, the antibody does recognize 
native PG treated with ABCase (Fig. 8 C), presumably via 
the unsaturated uronic acid that remains on the chondroitin 
sulfate GAG linkage region and the staining intensity is re- 
duced with twofold decrements of bound laG. 
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Figure 7. Size analysis of chondroitin sulfate and heparan sulfate 
GAG. [35S]GAG  chains released from purified syndecan were chro- 
matographed on Sepharose CL-6B and radioactivity in heparan sul- 
fate (HS) and chondroitin sulfate (CS) determined in column frac- 
tions by susceptibility to ABCase and nitrous acid,  respectively. 
([*] syndecan from untreated cells; [o] syndecan from cells cul- 
tured in TGF-B.) 
Figure 8. Recognition  of ABC- 
ase-treated syndecan by anti- 
chondroitin  sulfate antibody. 
Purified,  35SO4-1abeled syn- 
decan  from cells cultured  in 
TGF-3 was spotted on cationic 
nylon either directly (A), after 
alkali and ABCase treatment 
(B),  or  after  ABCase treat- 
ment alone (C). PG is spotted 
in twofold  decreasing dilutions 
containing  8,000, 4,000, and 
2,000 dpm. Subsequent  scintil- 
lation counting of the dots confirms quantitative retention of  the PG 
in A and loss of chondroitin sulfate-generated disaccharides but 
retention of heparan sulfate in B and C. The relative amounts of 
ABCase-generated linkage stubs present on the core protein are as- 
sessed by staining with antichondroitin sulfate antibody. 
This staining procedure shows that more chondroitin sul- 
fate chains are initiated on syndecan of cells in TGF-B (Fig. 
9). Comparison of [35S]sulfate-labeled  syndecan from cells 
cultured  in  the presence or absence of the growth  factor 
shows that the relative amounts of core protein per cell are 
the same, as shown previously (23). Nonetheless, autoradi- 
ography confirms that the PG from TGF-/3-treated cells con- 
tains at least twofold more radioactivity and that this differ- 
ence is largely reduced by ABease treatment. In addition, 
reaction of the ABCase-treated core protein with antichon- 
droitin sulfate antibody shows an approximately threefold in- 
crease in the number of unsaturated uronic acid residues re- 
tained on the core protein. This suggests that the augmented 
incorporation of radiolabel into chondroitin sulfate is be- 
cause of (a) increased length and (b) the initiation of  approxi- 
mately threefold more chains. 
Discussion 
Syndecan is an integral membrane PG found primarily on 
epithelia. Among the interesting features of this molecule is 
its complement of both chondroitin sulfate and heparan sul- 
fate GAG,  which has prompted investigation into the reg- 
ulation and significance of GAG attachment to the core pro- 
tein. The hybrid nature of the molecule was first shown on 
NMuMG mouse mammary epithelial cells in which 15-24 % 
of the GAG was reported to be in chondroitin sulfate and the 
remainder in heparan sulfate (20). Although it was proposed 
at that time that the proportions of the two GAG types might 
change with cell behavior, it was not clear what behavior 
would elicit the change. However, a recent report (23) dem- 
onstrates that treatment with TGF-B promotes FN accumula- 
tion, reduced proliferation and shape changes in these cells, 
as it does with other epithelia. In addition, it was shown that 
an increased amount of chondroitin sulfate was present at the 
cell surface despite unchanged amounts of syndecan core 
protein. This suggests either that the amount of chondroitin 
sulfate on syndecan is altered, or that the GAG is on a differ- 
ent PG whose appearance is regulated by the growth factor. 
Several approaches demonstrate that the increase in cell 
surface chondroitin sulfate is because of an augmented pro- 
portion on syndecan. Analysis of the molecule on density 
gradients shows an alteration in the density of the PG. Sec- 
ondly, the size of syndecan is increased, which is attributed 
to additional chondroitin sulfate as it is blocked by treatment 
with xyloside. Xylosides have previously been shown to af- 
fect chondroitin sulfate addition (30), although the concen- 
trations required to affect heparan sulfate addition are less 
well understood. In the case of syndecan, the attachment of 
both GAG types can be blocked, although chondroitin sulfate 
addition is affected at 10-fold lower concentrations than hep- 
aran sulfate. Blockage of  both types of  chains allows compar- 
ison of core protein sizes between treated and nontreated 
cells; the identical sizes suggest that additional chain addi- 
tion cannot be attributed to increased core protein size, as 
might occur as a result of splicing mechanisms during syn- 
thesis, or cross-linking to another PG. Thus, the data support 
the addition of more chondroitin sulfate to the syndecan core 
protein. This suggests that the amino acid sequence alone is 
not sufficient to designate numbers and/or types of chains 
and implicates an additional control mechanism. 
The change in structure of syndecan is not limited to chon- 
Rapraeger TGF-B Promotes Glycosaminoglycan  Addition  to Syndecan  2515 Figure 9. Comparison of ABCase-generated chon- 
droitin  sulfate linkage stubs on  syndecan  from 
cells cultured in the presence or absence of  TGF-B. 
Syndecan from equal numbers of cells cultured in 
the presence or absence of  TGF-/~  is spotted on cat- 
ionic nylon in twofold dilutions with or without 
prior ABCase treatment as in Fig. 8. Assessment 
of relative amounts of (a) core protein is done by 
staining with mAb 281.2; (b) [35S]GAG  is by au- 
toradiography and (c) linkage stubs is by staining 
with  antichondroitin  sulfate antibody  (antiCS). 
Scintillation counting of the dots following treat- 
ment showed that the PG from untreated cells con- 
rained 10,000 dpm, reduced to 8,400 by ABCase; 
PG  from TGF-/3-treated cells  contained 23,600 
dpm, reduced to 12,700 by ABCase. 
droitin sulfate. Heparan sulfate is increased 1.8-fold, and this 
is accounted for by an increase in its length. Although chon- 
droitin sulfate shows a similar increase in length, the sixfold 
increase in this GAG requires at least a threefold increase in 
chain number. This is confirmed by quantification of relative 
numbers of linkage sites.  Treatment of syndecan with ABC- 
ase cleaves all chondroitin sulfate chains, leaving a terminal 
unsaturated saccharide at the nonreducing end. Regardless 
of initial chain length, these would be one per chain. Detec- 
tion of these sites indicates an approximately threefold in- 
crease in syndecan from TGF-B-treated cells. 
The means by which TGF-B promotes the accumulation of 
additional chondroitin sulfate is  not clear.  The possibility 
that TGF-/~ selects a group of cells that are predisposed to 
express syndecan with a high chondroitin sulfate content is 
ruled out as the cells do not proliferate in the growth factor 
(23) and thus cannot generate a clonal population in response 
to the growth factor. Furthermore, TGF-/3 appears to pro- 
mote a net increase in the amount of chondroitin sulfate on 
most, if not all, cells rather than increasing the numbers of 
cells that are already expressing a PG rich in chondroitin sul- 
fate. This is shown by indirect staining with TSP, which de- 
tects only cells with the augmented amount of chondroitin 
sulfate; it fails to bind to chondroitin sulfate on nontreated 
cells, despite the presence of syndecan with ,,~20%  chon- 
droitin sulfate (34) but binds to chondroitin sulfate on most 
cells treated with TGF-~. 
Despite  the  overall  increase  in  GAG of TGF-B-treated 
cells, heterogeneity is observed on a single cell basis.  This 
heterogeneity is likely to be responsible for the large size dis- 
tribution of syndecan  reported earlier  (20).  TSP staining 
shows that some ceils express core protein that binds little 
TSP whereas others contain core protein, presumably richer 
in GAG, that readily binds the matrix component. The stain- 
ing method shows that both chondroitin sulfate and heparan 
sulfate vary, but does not allow simultaneous comparison of 
both GAG types on the same cell.  The biochemical data, 
therefore, reflect averages of this heterogeneity. 
Five ser-gly sequences (e.g.,  potential GAG attachment 
sites) in the syndecan core protein have been deduced from 
the cloned gene (29). It is not known how many of these sites 
are actually used.  If all five are used, the size and propor- 
tions of the GAG chains described here would dictate two 
heparan sulfate chains regardless of the presence of TGF-B 
and an increase from one chondroitin sulfate chain to three 
in the presence of TGF-fl (Table II). 
The role of chondroitin sulfate on syndecan remains un- 
clear.  The heparan sulfate chains serve to bind the PG to 
fibronectin (28), to collagen types I, III and V  (15) and to 
TSP (34). As shown here, either heparan sulfate or the en- 
hanced amount of chondroitin sulfate binds TSP to cell sur- 
faces. 
Although it provides an additional mechanism for binding 
TSP,  the chondroitin sulfate may interfere with other cell 
adhesion mechanisms (for review, see Ruoslahti [26]). Re- 
cently, Yamagata et al. (38) have demonstrated that chondroi- 
tin sulfate PG, but not isolated chains, blocks the binding of 
BHK cells to FN, laminin, vitronectin, and type I collagen; 
the authors postulate that the chains must be anchored to the 
core protein to generate a multivalent ligand that binds and 
may alter the conformation of cell surface receptors. Alter- 
natively, the core protein may position the GAG chains such 
that they block binding sites on the matrix ligand. Extending 
these findings to syndecan, the enhanced attachment of chon- 
droitin sulfate to this PG may orient the GAG such that it 
modifies the function of other cell surface matrix receptors; 
e.g., integrin-mediated binding to FN. 
Alternatively, it is speculated that chondroitin sulfate on 
the  same core protein with heparan  sulfate may block or 
Table II. Model of Syndecan 
No TGF-B  +TGF-~/ 
ChonSO4 chains 
Number  1  3 
Size  17 kD  31  kD 
Total  mass  17 kD  93  kD 
Percent of total  GAG  20%  43 % 
HepSO4 chains 
Number  2  2 
Size  36 kD  61  kD 
Total  mass  72  kD  122  kD 
Percent of total  GAG  80%  57% 
Core protein*  33  kD  33  kD 
Total  kilodaitons  122 kD  248  kD 
* Based on sequence data (29).  Actual core protein migrates anomalously on 
SDS-PAGE (29). 
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the extracellular matrix.  Preliminary data  (Rapraeger,  un- 
published observations)  show that chondroitin sulfate-rich 
syndecan isolated from TGF-fi-treated cells does bind FN 
affinity columns,  although only via heparan  sulfate.  How- 
ever,  it remains to be determined if the PG oriented by an- 
chorage in the plasma membrane is an equally effective re- 
ceptor. It is intriguing that two potential GAG anchorage sites 
on syndecan are near the plasma membrane whereas the re- 
maining three are near the distal end of the ectodomain. As 
discussed by Saunders et al. (29), the amino acid sequence 
of the distal  sites  are  characteristic  of chondroitin  sulfate 
attachment.  However,  it remains  to be confirmed  (a)  that 
TGF-fi treatment promotes attachment  of chondroitin sulfate 
to these sites, and (b) that the proximal sites (e.g., near the 
membrane) are exclusively decorated with heparan  sulfate. 
Indeed,  the possibility that heparan  sulfate is abolished on 
the core in some cell behaviors,  leaving solely chondroitin 
sulfate, has not been ruled out. 
In mouse tissues, syndecan is restricted primarily to epi- 
thelia (9).  Variation  is noted in the number of chondroitin 
sulfate and heparan  sulfate chains that it contains in simple 
compared to stratified epithelia (27), suggesting variability  in 
its molecular form in vivo.  Examination of its distribution 
during early development of the tooth suggests that it is ex- 
pressed at sites of epithelial/mesenchymal interactions (35). 
As TGF-/~ is localized to the mesenchyme of similar sites (10) 
and is believed to affect the epithelium, it is likely that the 
PG at these sites  is rich in chondroitin sulfate.  Treatment 
with xyloside, which blocks the addition of chondroitin sul- 
fate without disrupting heparan sulfate, may provide the op- 
portunity  to explore the roles of the respective GAG chains. 
This work was carried out by the expert technical assistance of Stuart Ras- 
mussen. 
Our work has been funded by National Institutes of Health grant HD 
21881. 
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